Business Context and Reporting Period
This Form 8-K, dated April 21, 2023, reports that Amphastar Pharmaceuticals, Inc. (Amphastar) entered into a Material Definitive Agreement to acquire the BAQSIMI glucagon nasal powder business from Eli Lilly and Company (Lilly). The filing also details the debt financing arrangements secured to fund this transaction.
Key Financial Metrics and Transaction Structure
The transaction involves significant cash outflows and new debt obligations structured as follows:
- Upfront Purchase Price: $500 million in cash payable at closing.
- Guaranteed Payment: $125 million payable on the first anniversary of the closing.
- Contingent Consideration: Up to $450 million in milestone payments based on annual and cumulative net sales of BAQSIMI over five years.
- Assumed Liabilities: Up to $125 million in earnout obligations previously held by Lilly, tied to sales milestones of $350 million, $400 million, and $600 million.
- Debt Financing: Amphastar secured commitments for a $500 million senior secured term loan and a $150 million senior secured revolving credit facility to finance the acquisition and refinance existing debt.
The filing does not provide current revenue, profit, cash flow, or margin data for Amphastar, as this is a current report regarding a specific event rather than a periodic financial statement.
Material Changes and Milestones
The primary material change is the potential expansion of Amphastar's product portfolio through the acquisition of BAQSIMI. The contingent consideration structure creates future financial obligations dependent on performance:
- Annual Sales Milestones: Payments of $100 million each if annual net sales reach $175 million; up to two payments of $100 million each if annual net sales reach $200 million.
- Cumulative Sales Milestone: A one-time payment of $150 million if total cumulative net sales reach $950 million over the first five years post-closing.
Outlook, Risks, and Contingencies
Conditions Precedent: Closing is subject to customary conditions, including the expiration of the Hart-Scott-Rodino Antitrust waiting period, regulatory approvals, and the absence of a material adverse effect.
Termination Risks: The agreement includes a termination right if the acquisition is not consummated by October 21, 2023. If terminated due to a failure to obtain regulatory approvals, Amphastar must pay a $5 million termination fee to Lilly.
Operational Transition: Amphastar expects to enter into Intellectual Property, Manufacturing Services, and Transition Services agreements with Lilly to support the business transfer.
Financing Contingency: The debt financing is contingent on the execution of definitive documentation and the consummation of the acquisition. Actual terms may differ from the commitment letter.
Investor Verification Checklist
- Verify the final terms of the definitive debt documentation, as actual terms may differ from the commitment letter.
- Monitor the status of regulatory approvals and the Hart-Scott-Rodino waiting period to assess closing certainty.
- Review the upcoming Form 10-Q for the full text of the Asset Purchase Agreement and Commitment Letter.
- Assess the impact of the $500 million new debt and potential $450 million contingent liability on Amphastar's leverage ratios and liquidity.
- Confirm the timeline for the transition of manufacturing and supply services from Lilly to Amphastar.